RxDoctor Payments Data

Joseph Sanchez, MD

Internal Medicine · Rancho Mirage, CANPI 1942293568

Payments from drug & device makers

$425in general payments, 2019–2025

Across 19 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$131
  • AstraZeneca$97
  • Otsuka America Pharmaceutical, Inc.$61
  • Amgen$47
  • Travere Therapeutics, Inc.$24
  • Boston Scientific$19
  • plus $45 from 3 others

What the payments were for

  • Food & beverage$35183%
  • Education$7317%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$425 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$115,469
Medicare patients
440
Services billed
998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$37,012
FarxigaDapagliflozin Propanediol29$30,271
VelphoroSucroferric Oxyhydroxide11$24,183
EliquisApixaban14$20,722
JardianceEmpagliflozin17$19,776
LokelmaSodium Zirconium Cyclosilicate11$8,233
Sevelamer Carbonate18$4,713
PaxlovidNirmatrelvir/Ritonavir11$1,429
Nebivolol Hcl12$1,325
Amlodipine Besylate86$975
Cefpodoxime Proxetil17$932
Metoprolol Succinate47$816
Valsartan25$804
Carvedilol83$803
Gabapentin41$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$97$38,50440 claims
Novo NordiskOzempic$131$37,01237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →